Rigosertib

Rigosertib
Names
	IUPAC name (2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}phenyl)glycine
	Systematic IUPAC name (2-Methoxy-5-{[(E)-2-(2,4,6-trimethoxyphenyl)ethene-1-sulfonyl]methyl}anilino)acetate
	Other names ON-01910
Identifiers
CAS Number	592542-59-1 ;
3D model (JSmol)	: Interactive image;
ChEBI	CHEBI:145417;
ChEMBL	ChEMBL1241855; ChEMBL2013119;
ChemSpider	5293927;
IUPHAR/BPS	7833;
KEGG	D10154;
PubChem CID	6918736;
UNII	67DOW7F9GL ;
CompTox Dashboard (EPA)	DTXSID30207984 ;
	InChI InChI=1S/C21H25NO8S/c1-27-15-10-19(29-3)16(20(11-15)30-4)7-8-31(25,26)13-14-5-6-18(28-2)17(9-14)22-12-21(23)24/h5-11,22H,12-13H2,1-4H3,(H,23,24)/b8-7+ Key: OWBFCJROIKNMGD-BQYQJAHWSA-N;
	SMILES : COC1=C(C=C(C=C1)CS(=O)(=O)/C=C/C2=C(C=C(C=C2OC)OC)OC)NCC(=O)O;
Properties
Chemical formula	C21H25NO8S
Molar mass	451.49 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Rigosertib (ON-01910 sodium salt, with Estybon as trade name) is a synthetic benzyl styryl sulfone in development by Onconova Therapeutics.^[2] Rigosertib is in phase III clinical trials for the treatment of chronic myelomonocytic leukemia.^[3]

Its geometrical isomer (Z)-ON 01910·Na has less cytotoxicity on cancer cells.

Mechanism

Rigosertib is a microtubule-destabilizing agent.^[4]

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.